Axsome Therapeutics, Inc. (AXSM) - Stock Analysis
Last updated: Jan 19, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Axsome Therapeutics is a hot idea with key upcoming FDA priority review of AXS-05 and NDA filing for AXS-12, strong Q3 revenue growth, and robust technical momentum. Despite operating losses and governance risks, its near-term regulatory catalysts provide potential for significant short-term price appreciation.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠High gross-margin ⢠Substantial cash ⢠Elevated leverage AXSM has very high gross margins and ample cash cushioning near-term liquidity but remains loss-making with heavy operating spend, elevated leverage, and rich market valuation.
Price Behavior
Key Price Behavior Insights: ⢠Support base ⢠Testing resistance ⢠Post-dip recovery Support Level: $145â$150 Resistance Level: $178â$182 AXSM has rebounded from a $145â$150 support base to test $178â$182 resistance, showing short-term bullish momentum after a late-December drop to ~ $148 but with nearby resistance and volatility that warrant caution.
Sentiment & News
Key News Insights: ⢠Priority review ⢠Strong revenues ⢠Institutional buying Axsome gained strong investor momentum from late 2025 into early 2026 on FDA priority review for AXSâ05 (PDUFA Apr 30, 2026), supportive AXSâ12 preâNDA feedback, robust Q4/FY revenue growth, and rising institutional ownership.
AI Summary
Axsome is transitioning from a binary biotech into a commercial-growth biopharmaâdriven by AUVELITY revenue and very high product marginsâmaking it a richly valued, executionâdependent growth story that will be validated by sustained revenue/NCFO improvement and favorable AXSâ05/AXSâ12 outcomes but is highly vulnerable to worsening GTN/payer dynamics, receivables/cash conversion issues, or regulatory setbacks.
Description
Axsome Therapeutics is a U.S.-based biopharmaceutical company developing treatments for central nervous system disorders. Its late-stage pipeline includes a depression candidate (AXS-05) with additional trials in Alzheimer's-related agitation and prior smoking cessation data, a migraine treatment that completed Phase III testing (AXS-07), and Phase III programs for narcolepsy (AXS-12) and fibromyalgia (AXS-14). The company has a research collaboration with Duke University and was founded in 2012 in New York City.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Jan 1 | Jan 8 | AXSM | Axsome Therapeutics, Inc. | Axsome Therapeutics is a hot idea with key upcoming FDA priority review of AXS-05 and NDA filing for AXS-12, strong Q3 revenue growth, and robust technical momentum. Despite operating losses and governance risks, its near-term regulatory catalysts provide potential for significant short-term price appreciation. | Closed | -8.3% |